Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Files Protease Inhibitor/NRTIs Combo for HIV Infection in Japan
February 21, 2019
- Ono/Seikagaku’s Novel Osteoarthritis Drug Hits Primary Goal in Japan PIII
February 20, 2019
- EA Pharma Grabs Japan Rights to Dr. Falk’s Liver Therapy
February 20, 2019
- Suzuken, Toho to Set Up Generic JV, Share Systems in Specialty Pharma Business
February 20, 2019
- Shionogi, FunPep Link to Joint Research for Antibody-Inducing Peptides in Pain Field
February 19, 2019
- Taiyo Forms Capital Alliance with Regenerative Medicine Biotech
February 19, 2019
- As Japan Goes Digital on Package Inserts, Distributors Fret Proposed Paper-Based Rule on “1st Delivery”
February 18, 2019
- Crysvita Shows Long-Term Benefits in Pediatric XLH Study
February 18, 2019
- Shire’s Product Sales Up 3.9% in 2018: Takeda
February 18, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Merck Serono Japan to Be Renamed “Merck Biopharma” in April
February 18, 2019
- Rexulti Misses Primary Goal in Global PIII for Bipolar I Disorder: Otsuka, Lundbeck
February 18, 2019
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
- Mitsubishi Tanabe to Begin Clinical Study in US for c-Met Targeting ADC
February 15, 2019
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
- Kowa to Reshuffle Pharma Business in April, Launching New Company for LLP Operations
February 15, 2019
- Armed with Positive Data, G47Δ Could Reach Filing in May as Japan’s 1st Oncolytic Virus
February 14, 2019
- Recordati Ratcheting Up Japan Biz, Set to Enrich Rare Disease Portfolio
February 14, 2019
- Upbeat Global Brands Drive Otsuka Sales in 2018
February 14, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…